Brentuximab vedotin (Adcetris®) is indicated for the treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/12/2019|
|Rapid review completed||29/01/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||05/02/2020|
|Pre-submission consultation with Applicant||19/05/2020|
|Current status||Awaiting HTA submission from Applicant|